Introduction
This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharmaceutical sector. It encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights
Reasons to Purchase
Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector Analyze how Schering-Plough's acquisition of Organon Biosciences will drive notable therapeutic diversification for the company Assess Schering-Plough's continued forecast recovery (CAGR of 7.9% out to 2012) following patent expiry for Claritin in 2001
Schering-Plough Corporation: PharmaVitae Profile features primary data, independent analysis and fresh opinions on markets, trends and players on the Healthcare market sector.